LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Inicio・Lista de Acciones・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Cerrado

SectorSalud

8.99 1.58

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.83

Máximo

Métricas clave
By Trading Economics
Ingresos	-2.7M -24M
Ventas	29M 155M
Margen de beneficio	-15.787
Empleados	499
EBITDA	-1M -5.8M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+79.03% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	461M 2.3B
Apertura anterior	7.41
Cierre anterior	8.99

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

323 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.925 / 7.38 Soporte y Resistencia

Amicus Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 nov 2025, 21:36 UTC

Ganancias

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 nov 2025, 21:22 UTC

Ganancias

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 nov 2025, 00:00 UTC

Charlas de Mercado

India Inflation Poised to Hit New Low -- Market Talk

9 nov 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 nov 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 nov 2025, 21:05 UTC

Ganancias

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 nov 2025, 21:04 UTC

Ganancias

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 nov 2025, 21:03 UTC

Ganancias

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 nov 2025, 20:49 UTC

Ganancias

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 nov 2025, 20:49 UTC

Ganancias

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 nov 2025, 20:45 UTC

Ganancias

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 nov 2025, 20:45 UTC

Ganancias

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 nov 2025, 20:42 UTC

Ganancias

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 nov 2025, 20:42 UTC

Ganancias

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 nov 2025, 20:41 UTC

Ganancias

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 nov 2025, 20:41 UTC

Ganancias

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 nov 2025, 20:39 UTC

Ganancias

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 nov 2025, 20:39 UTC

Ganancias

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 nov 2025, 20:38 UTC

Ganancias

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 nov 2025, 20:38 UTC

Ganancias

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 nov 2025, 20:38 UTC

Ganancias

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 nov 2025, 13:10 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 03:50 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Ganancias

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q EPS $9.89 >CSU.T

Comparación entre iguales

Cambio de precio

Amicus Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

79.03% repunte

Estimación a 12 meses

Media 15.88 USD 79.03%

Máximo 21 USD

Mínimo 11 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.925 / 7.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

323 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.